Felix Ratjen, MD PhD

Professor
University of Toronto

Poster(s):

(122) Changes in the lung clearance index in individuals who are newborn screening positive for CF with an inconclusive diagnosis (CFSPID)
Thursday, November 3, 2022
12:00 PM – 12:40 PM ET
(160) Monitoring Response to Elexacaftor/Tezacaftor/Ivacaftor Treatment in Pediatric Cystic Fibrosis Lung Disease using Free-Breathing Magnetic Resonance Imaging
Thursday, November 3, 2022
12:00 PM – 12:40 PM ET
(161) Elexacaftor/Tezacaftor/Ivacaftor reduces trapped gas in children with cystic fibrosis
Thursday, November 3, 2022
12:45 PM – 1:25 PM ET
(163) Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children 6 years and older with cystic fibrosis and ≥1 F508del allele: 96-week interim results from an open-label extension study
Thursday, November 3, 2022
12:45 PM – 1:25 PM ET
(165) Xe MRI detects lung ventilation improvement in children with CF treated with ELX/TEZ/IVA in a multi-site study
Thursday, November 3, 2022
12:45 PM – 1:25 PM ET
(173) Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in children with cystic fibrosis: The Pediatric PROMISE study
Thursday, November 3, 2022
12:45 PM – 1:25 PM ET
(176) How frequently should the lung clearance index be measured in children with cystic fibrosis?
Thursday, November 3, 2022
12:00 PM – 12:40 PM ET
(177) Elexacaftor/tezacaftor/ivacaftor treatment in pediatric cystic fibrosis lung disease reduces ventilation heterogeneity measured with hyperpolarized ¹²⁹Xe multiple-breath washout MRI
Thursday, November 3, 2022
12:45 PM – 1:25 PM ET
(213) Fecal Microbiota with 1 Month of Elexacaftor/Tezacaftor/Ivacaftor in Pediatric Patients with Cystic Fibrosis: Preliminary Findings from PROMISE Pediatrics Study
Thursday, November 3, 2022
12:45 PM – 1:25 PM ET
(224) Elexacaftor/Tezacaftor/Ivacaftor alters Gastrointestinal Symptoms and Inflammation: Report of PROMISE Peds GI
Thursday, November 3, 2022
12:00 PM – 12:40 PM ET
(429) Myeloperoxidase in extracellular vesicles isolated from airways of children with cystic fibrosis
Thursday, November 3, 2022
12:45 PM – 1:25 PM ET
(492) The effect of antibiotic changes during treatment of cystic fibrosis pulmonary exacerbations
Thursday, November 3, 2022
12:00 PM – 12:40 PM ET
(535) Detection of Staphylococcus aureus in exhaled breath of children with cystic fibrosis
Thursday, November 3, 2022
12:45 PM – 1:25 PM ET
(693) A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 2 Through 5 Years of Age with Cystic Fibrosis and at Least One F508del Allele
Thursday, November 3, 2022
12:45 PM – 1:25 PM ET